Novo Nordisk A/S (NVO) Stock
NYSENVO has an Alpha Score of 41 out of 100 (weak), computed on Oct 26, 2026 from 3 of 4 sub-scores. 14 members of Congress disclosed 35 trades in NVO since 2016: 18 purchases and 17 sales, most recently Kevin Hern (sale, Sep 10, 2026). 7 of the hedge funds AlphaScala tracks reported NVO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $145.37M. Its trailing P/E ratio is 9.9 and its net margin 35.4% (key statistics as of Oct 29, 2026).
What is NVO's Alpha Score?
How it works →Alpha Score of 40 reflects weak overall profile with poor momentum, moderate value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 26, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Novo Nordisk A/S (NVO)?
Most recent: Kevin Hern (sale, Sep 10, 2026); records start Oct 11, 2016.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-09-10 | sale | $1k – $15k |
| Kevin Hern R-OK · House | 2026-08-31 | partial sale | $1k – $15k |
| Scott Franklin R-FL · House | 2026-08-26 | purchase | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $15k – $50k |
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Marjorie Taylor Greene R-GA · House | 2025-10-15 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded NVO, with filing lags →Which hedge funds own NVO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 3.03M | $145.37M | -11% |
| Millennium Management Israel Englander | 2.04M | $97.60M | +45% |
| Marshall Wace | 1.71M | $81.84M | -44% |
| Maverick Capital Lee Ainslie | 1.65M | $79.29M | -20% |
| Citadel Ken Griffin | 1.37M | $65.50M | -50% |
| D.E. Shaw David Shaw | 698K | $33.44M | -66% |
| Point72 Steve Cohen | 29K | $1.40M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are NVO's key statistics?
Key statistics as of Oct 29, 2026
How does NVO's valuation compare with the Healthcare sector?
| Metric | NVO | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 9.9 | 27.1 | 97 |
| Net margin | 35.35% | 5.48% | 139 |
| Return on equity | 59.09% | 6.84% | 158 |
| Dividend yield (payers) | 1.00% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
NVO price chart
Powered by TradingViewWhat does Novo Nordisk A/S do?
Novo Nordisk is a leading global pharmaceutical company headquartered in Denmark that specializes in developing and manufacturing medicines to treat serious chronic diseases. The company focuses on four primary therapeutic areas: diabetes, obesity, cardiovascular disease, and rare diseases including hemophilia and growth disorders. Its product portfolio includes diabetes treatments like Tresiba and Rybelsus, obesity medications such as Wegovy, cardiovascular and rare disease therapies, and hormone replacement treatments. Novo Nordisk operates manufacturing facilities across multiple continents and maintains research and development centers worldwide, serving millions of patients globally. The company is backed by the Novo Nordisk Foundation, one of the world's largest philanthropies, which influences its approach to healthcare innovation and patient access. Founded on principles emphasizing scientific excellence and compassion, Novo Nordisk combines breakthrough pharmaceutical research with a commitment to expanding medicine accessibility and working toward disease prevention and cure.